10X Genomics
VerifiedBuilding tools for scientific discovery that reveal and address the true complexities of biology and disease
Launch date
Employees
Ownership
Market cap
$4.7b
Net debt
$9.8b
Firm valuation
$8.2b (Public information from 2022)
Share price
$41.72 TXG
Pleasanton California (HQ)
Deals in current and previous year:
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 224m | 272m | 449m | 559m |
| % growth | - | - | - | - | 22 % | 65 % | 24 % |
| EBITDA | - | - | - | (20.9m) | (473m) | (24.5m) | (71.8m) |
| % EBITDA margin | - | - | - | (9 %) | (174 %) | (5 %) | (13 %) |
| Profit | - | - | - | (28.2m) | (494m) | (41.8m) | (79.1m) |
| % profit margin | - | - | - | (13 %) | (182 %) | (9 %) | (14 %) |
| EV / revenue | - | - | - | 28.2x | 48.8x | 33.9x | 13.4x |
| EV / EBITDA | - | - | - | -295.0x | -28.0x | - | -104.0x |
| R&D budget | - | - | - | 74m | - | - | - |
| R&D % of revenue | - | - | - | 33 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $3m | Series A | |
| N/A | $22.4m | Series A Not yet verified | |
| $55.5m | Series B | ||
| $55m | Series C | ||
| $50m | Series D | ||
| $75m | Debt | ||
* | $35m Valuation: $1.3b | Late VC | |
| N/A | $390m Valuation: $3.7b | IPO | |
| Total Funding | $199m | ||
Recent News about 10X Genomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by 10X Genomics
Edit
ACQUISITION by 10X Genomics Aug 2018
ACQUISITION by 10X Genomics Oct 2020
ACQUISITION by 10X Genomics Dec 2018
ACQUISITION by 10X Genomics Oct 2020